Cargando…
PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series
Hypercytokinemia induced by coronavirus disease-19 (COVID-19) is associated with severe pulmonary involvement, which may lead to respiratory failure. These conditions play an important role in the worsening of clinical symptoms in patients with severe COVID-19. There is no established treatment for...
Autores principales: | Kuwana, Tsukasa, Kinoshita, Kosaku, Hirabayashi, Marina, Ihara, Shingo, Sawada, Nami, Mutoh, Tomokazu, Yamaguchi, Junko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040694/ https://www.ncbi.nlm.nih.gov/pubmed/33854342 http://dx.doi.org/10.2147/IDR.S299023 |
Ejemplares similares
-
The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP)
por: Kuwana, Tsukasa, et al.
Publicado: (2022) -
Relationship between brain volume reduction during the acute phase of sepsis and activities of daily living in elderly patients: A prospective cohort study
por: Hosokawa, Toru, et al.
Publicado: (2023) -
Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021) -
Is it true that PMX-DHP can improve lung oxygenation?
por: Ikeda, T, et al.
Publicado: (2003) -
Effect of PMX-DHP according to differences in infection site
por: Ikeda, T, et al.
Publicado: (2001)